Cardiomed S.R.L.

Cluj-Napoca 26 trials 11 recruiting

26 Registered trials

11 Currently recruiting

Organisation

Cardiomed S.R.L.

Location

Cluj-Napoca, Romania

Identifier

ORG-100046981

Address

Strada Republicii Nr 30, 400015, Romania

Departments

#3240: Cardiology
Cabinet Oncologie medicala
Departament Otorinolaringologie (ORL)
Medical Oncology
N/A
Oncologie
Oncologie Medicala
Oncology
Secţia Oncologie Medicală

Clinical trials at this site (26)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended

2022-501483-18-00 Advanced Non-Small Cell Lung Cancer 10 2025-03-28
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended

2023-505615-21-00 Muscle Invasive Bladder Cancer 5 2021-04-28
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Esophageal Carcinoma 5 2021-07-21
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Stage IV non small-cell lung cancer 5 2021-04-21
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26